A Study of BL-B01D1+PD-1 Monoclonal Antibody in Patients With Unresectable Locally Advanced or Recurrent Metastatic Triple-negative Breast Cancer
Clinical trial NCT06471205 · RECRUITING
Trial details
- NCT number
- NCT06471205
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-08-02
- Primary completion
- 2026-12-01
- Enrollment
- 52
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.